Study S001914

New Formulation of Semaglutide in the Treatment of Type 2 Diabetes in Argentina: a Prospective, Multicenter, Real-world Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07621419
Acronym: SEMA-REAL ARG
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 145
Start: 2025-08-04
Primary completion: 2027-12-31
Lead sponsor: Hospital Italiano de Buenos Aires
Conditions: Diabetes Mellitus
Interventions: DRUG:semaglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in glycated hemoglobin (HbA1c) levels from baseline to 3, 6, and 12 months of follow-up. [Baseline, 3 months, 6 months, and 12 months.]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006504	PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes. Saravanan P, Advances in therapy	2024	Nonrandomized study	PMID 39316289 DOI	registry reference BACKGROUND:39316289
R0006404	Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Mahapatra MK, Reviews in endocrine & metabolic disorders	2022	Narrative review	PMID 34993760 DOI	registry reference BACKGROUND:34993760
R0018373	PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Aroda VR, Diabetes care	2019	Randomized trial	PMID 31186300 DOI	registry reference BACKGROUND:31186300